近期CXO行业的平静只停留在表面,实则草木皆兵。半个月前,药明康德宣布剥离海外细胞基因治疗业务,这两天药明系再次大调整海外业务。从1月6日晚上到1月7日早上,药明生物紧急召开了两场电话说明会,都围绕与“默沙东的疫苗工厂回售交易”后的业务更新调整进行说明。药明生物表示,出售爱尔兰疫苗生产基地与生物安全法案毫无关系,纯粹是因为自身想要优化资源配置。药明生物2018年成立专门代工疫苗生产的子公司药明海德...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.